These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21161021)

  • 1. Pericarditis and chronic inflammatory demyelinating polyneuropathy during therapy with pegylated interferon alfa-2a for chronic hepatitis C.
    Nishio K; Konndo T; Okada S; Enchi M
    World J Hepatol; 2010 Sep; 2(9):358-61. PubMed ID: 21161021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alfa-2a in a patient with chronic hepatitis C virus infection: a case report.
    Lahbabi M; Ghissassi M; Belahcen F; Ibrahimi SA; Aqodad N
    J Med Case Rep; 2012 Sep; 6():278. PubMed ID: 22947101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report.
    Niazi MA; Azhar A; Tufail K; Feyssa EL; Penny SF; McGregory M; Araya V; Ortiz JA
    World J Hepatol; 2010 Apr; 2(4):162-6. PubMed ID: 21160989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic inflammatory demyelinating polyneuropathy followed by systemic lupus erythematosus and Sjögren syndrome: a case report].
    Hatano T; Fukuda M; Shiotsuki H; Miwa H; Urabe T; Mizuno Y
    Rinsho Shinkeigaku; 2006 Mar; 46(3):203-9. PubMed ID: 16642931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection.
    Khiani V; Kelly T; Shibli A; Jensen D; Mohanty SR
    World J Gastroenterol; 2008 Jan; 14(2):318-21. PubMed ID: 18186575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
    Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
    N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
    Baker DE
    Rev Gastroenterol Disord; 2003; 3(2):93-109. PubMed ID: 12776006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of peginterferon alfa-2a (40KD) treatment in patients with chronic hepatitis B infection: an observational, multicenter, open label, non-interventional study in Turkish patients.
    Tözün N; Sezgın O; Gülşen M; Kacar S; Yenıce N; Yilmaz Ş; Hülagü S; Kantarçeken B; Yakaryilmaz F; Yurcı A; Serez KM; Bahçecıoğlu H; Bağci S
    Turk J Gastroenterol; 2012; 23(5):552-9. PubMed ID: 23161301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain.
    Turnes J; Romero-Gómez M; Planas R; Solà R; García-Samaniego J; Diago M; Crespo J; Calleja JL; Rubio-Terrés C; Ventayol P
    Gastroenterol Hepatol; 2013 Nov; 36(9):555-64. PubMed ID: 24119723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.
    Manns M; Marcellin P; Poordad F; de Araujo ES; Buti M; Horsmans Y; Janczewska E; Villamil F; Scott J; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):414-26. PubMed ID: 24907224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alpha 2b in a patient with HIV/HCV coinfection: case report].
    Bassetti BR; Trés ES; Ciríaco JG; Pinto Neto LF
    Rev Soc Bras Med Trop; 2010; 43(1):89-91. PubMed ID: 20305976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of chronic inflammatory demyelinating polyradiculoneuropathy after treatment with pegylated interferon α-2a in a patient with chronic hepatitis B virus infection].
    Naito H; Takeda I; Segawa A; Tsuge M; Maruyama H; Matsumoto M
    Rinsho Shinkeigaku; 2016 Oct; 56(10):672-677. PubMed ID: 27680223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy with peginterferon alfa in a patient with polyneuropathy caused by hepatitis C-associated vasculitis].
    Zoras C
    Med Klin (Munich); 2006 Mar; 101(3):243-7. PubMed ID: 16648982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alfa-2a in patients with chronic hepatitis C.
    Zeuzem S; Feinman SV; Rasenack J; Heathcote EJ; Lai MY; Gane E; O'Grady J; Reichen J; Diago M; Lin A; Hoffman J; Brunda MJ
    N Engl J Med; 2000 Dec; 343(23):1666-72. PubMed ID: 11106715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and cost-utility of the treatment of chronic hepatitis B with peginterferon alfa-2a, interferon alfa, and lamivudine in Lithuania.
    Vanagas G; Padaiga Z; Mickevičienė A
    Medicina (Kaunas); 2010; 46(12):835-42. PubMed ID: 21532288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An unusual axonal polyneuropathy induced by low-dose interferon alfa-2a.
    Rutkove SB
    Arch Neurol; 1997 Jul; 54(7):907-8. PubMed ID: 9236581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.